[go: up one dir, main page]

NI201000132A - INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3. - Google Patents

INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3.

Info

Publication number
NI201000132A
NI201000132A NI201000132A NI201000132A NI201000132A NI 201000132 A NI201000132 A NI 201000132A NI 201000132 A NI201000132 A NI 201000132A NI 201000132 A NI201000132 A NI 201000132A NI 201000132 A NI201000132 A NI 201000132A
Authority
NI
Nicaragua
Prior art keywords
cxccr3
receptor inhibitors
chemokines receptor
benzosulfonamide
sulfamido
Prior art date
Application number
NI201000132A
Other languages
English (en)
Inventor
s thorpe David
Smrcina Martin
D Cabel Dagmar
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI201000132A publication Critical patent/NI201000132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Esta invención se dirige a un compuesto 3 - ( amido o sulfamido) - 4 - ( 4 - azinil sustituido ) benzamida o benzosulfonamida como se define en la presente memoria. El compuesto 3 - ( amido o sulfamido) - 4 - ( 4 - azinil sustituido ) benzamida o benzosulfonamida es útil como inhibidor del receptor de quimioquinas CxCR3, y para prevenir o tratar una enfermedad mediada por el receptor de quimioquinas CxCR3 o afecciones relacionadas con la misma en un paciente que lo necesite.
NI201000132A 2008-02-19 2010-07-29 INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3. NI201000132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
NI201000132A true NI201000132A (es) 2011-03-16

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000132A NI201000132A (es) 2008-02-19 2010-07-29 INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3.

Country Status (25)

Country Link
US (1) US8268828B2 (es)
EP (1) EP2262784B1 (es)
JP (1) JP2011512412A (es)
KR (1) KR20100123835A (es)
CN (1) CN102007108A (es)
AR (1) AR070430A1 (es)
AU (1) AU2009215643A1 (es)
BR (1) BRPI0908815A2 (es)
CA (1) CA2715557A1 (es)
CL (1) CL2009000368A1 (es)
CO (1) CO6241113A2 (es)
CR (1) CR11604A (es)
DO (1) DOP2010000254A (es)
EC (1) ECSP10010409A (es)
IL (1) IL207597A0 (es)
MA (1) MA32191B1 (es)
MX (1) MX2010008397A (es)
NI (1) NI201000132A (es)
NZ (1) NZ587380A (es)
PE (1) PE20091576A1 (es)
RU (1) RU2010138577A (es)
SV (1) SV2010003648A (es)
TW (1) TW200948791A (es)
WO (1) WO2009105435A1 (es)
ZA (1) ZA201005314B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
JP5807971B2 (ja) 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
CA2834199C (en) * 2011-07-18 2020-01-07 Merck Patent Gmbh Benzamides as allosteric modulators of the fsh receptor
EP2601950A1 (en) 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
CN104080784B (zh) 2012-01-10 2017-07-18 默克专利有限公司 用作卵泡刺激素调节剂的苯甲酰胺衍生物
EP2809668B1 (en) 2012-02-02 2017-04-12 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
EP2666769A1 (en) 2012-05-23 2013-11-27 Sanofi Substituted B-amino acid derivatives as CXCR3 receptor antagonist
CN105658649B (zh) 2013-07-22 2019-03-22 爱杜西亚药品有限公司 1-(哌嗪-1-基)-2-([1,2,4]三唑-1-基)-乙酮衍生物
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
EP3193600A4 (en) * 2014-09-10 2018-05-23 Epizyme, Inc. Smyd inhibitors
PE20171100A1 (es) 2015-01-15 2017-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
AU2018244211B2 (en) * 2017-03-26 2022-05-12 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
CN115974766B (zh) * 2023-01-04 2025-05-16 中国药科大学 N-苄基-3-苯基酰胺类衍生物、包含其的药物组合物及其应用
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719660A (en) 1969-06-13 1973-03-06 Takeda Chemical Industries Ltd 2-furfurylthioinosine-5'-phosphate compounds
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
EP1554253A4 (en) 2002-06-03 2006-09-20 Smithkline Beecham Corp IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
EP1856097B1 (en) * 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CA2598459A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
RU2007134260A (ru) 2005-02-16 2009-03-27 Шеринг Корпорейшн (US) Пиразинилзамещенные пиперазин-пиперидины с антагонистической активностью в отношении cxcr3
US20080312215A1 (en) * 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
JP2009511582A (ja) 2005-10-11 2009-03-19 シェーリング コーポレイション Ｃｘｃｒ３拮抗薬活性を有する置換複素環式化合物
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
RU2008141368A (ru) 2006-03-21 2010-04-27 Шеринг Корпорейшн (US) Новые гетероциклические соединения замещенного пиридина с антагонистической активностью схсr3
CA2658417A1 (en) 2006-07-14 2008-01-17 Schering Corporation Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
CO6241113A2 (es) 2011-01-20
ECSP10010409A (es) 2010-09-30
CN102007108A (zh) 2011-04-06
MX2010008397A (es) 2010-08-23
SV2010003648A (es) 2011-01-31
IL207597A0 (en) 2010-12-30
ZA201005314B (en) 2011-03-30
RU2010138577A (ru) 2012-03-27
CL2009000368A1 (es) 2009-06-26
WO2009105435A1 (en) 2009-08-27
EP2262784B1 (en) 2014-04-16
NZ587380A (en) 2011-09-30
AR070430A1 (es) 2010-04-07
MA32191B1 (fr) 2011-04-01
DOP2010000254A (es) 2010-08-31
JP2011512412A (ja) 2011-04-21
TW200948791A (en) 2009-12-01
AU2009215643A1 (en) 2009-08-27
US20100305088A1 (en) 2010-12-02
KR20100123835A (ko) 2010-11-25
CR11604A (es) 2010-10-05
PE20091576A1 (es) 2009-11-05
US8268828B2 (en) 2012-09-18
BRPI0908815A2 (pt) 2019-09-24
EP2262784A1 (en) 2010-12-22
CA2715557A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
NI201000132A (es) INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxcCR3.
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
BR112012008677A2 (pt) compostos amino-pirimidina como inibidores de tbkl e/ou ikk epsilon
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
CR20110103A (es) Heteroarilos sustituidos
CR20110100A (es) Nuevos derivados de sulfamida sustituida
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
GT200600046A (es) Terapia de combinacion
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CL2010001474A1 (es) Compuestos derivados de tiofeno o tiazol sustituidos, inhibidores de pi3k; composicion farmaceutica; utiles en el tratamiento del cancer, inflamacion y en el tratamiento de trastornos cardiovasculares.
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
HN2005036256A (es) Derivados fusionados de pirazol y metodos de tratamiento de trastornos metabolicos con estos
CR11290A (es) Derivados de ciclopropilamida
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
ECSP10010025A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
BRPI0906522A2 (pt) Sulfonamidas como antagonistas de orexina
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
HN2012001160A (es) Agonistas mglu2
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
IL209629A0 (en) Pyrrolidin - 3 - ylmethyl - amine as orexin antagonists